S. Kurtin

University of Arizona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Tanya G. K. Bentley

Partnership for Health Analytic Research

E. Chang

University of California, Los Angeles

Michael E. Petrone

Onconova Therapeutics (United States)

Robert Knight

King's College London

Michael S. Broder

Partnership for Health Analytic Research

Daruka Mahadevan

Jawaharlal Institute of Post Graduate Medical Education and Research

Thomas J. McKearn

Onconova Therapeutics (United States)

Christopher R. Cogle

University of Florida

Alan F. List

Precision BioSciences (United States)

Scott Megaffin

Onconova Therapeutics (United States)

Cooperative Institutions

University of Arizona

University of Arizona Cancer Center

Arizona Oncology

Partnership for Health Analytic Research

University of South Florida

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

University of California, Los Angeles

Mayo Clinic

Mayo Clinic in Arizona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Pilot Testing of a Health and Life Management Mobile Health Application for Caregivers and Patients Living with Myelodysplastic Syndromes

Leukemia Research (2017)

S. Kurtin L. Harrison Tracey Iraca Amar Hassan Khamis

Depression

Mobile phone

10.1016/s0145-2126(17)30336-3

Cite

Citations (3)

Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

American Journal of Clinical Oncology (2012)

Daruka Mahadevan Pavani Chalasani Diane Rensvold S. Kurtin Chris Pretzinger

Objectives: AEG35156 is an antisense oligonucleotide (ASO) that targets the X-linked inhibitor of apoptosis mRNA. Preclinical studies showed potent activity of AEG35156 in combination with gemcitabine in pancreatic ductal adenocarcinoma (PDA). A phase I study was conducted to establish the maximum-tolerated dose, safety, and antitumor activity of AEG35156 plus gemcitabine in metastatic PDA. Methods: Fourteen patients with metastatic PDA were enrolled. Nine patients were treated at 350 mg IV and 5 patients at 500 mg IV of AEG35156, 3 weeks on/1 week off of a 28-day cycle. Gemcitabine was administered at 1000 mg/m2 IV over 30 minutes immediately after AEG35156 in both groups. Because of perceived neurotoxicity dose deescalation to 350 mg was recommended. Results: All 14 patients were evaluable for tolerability and toxicity. Toxicities include neutropenia (grade 3/4, 6 patients), thrombocytopenia (grade 3, 2 patients), peripheral neuropathy (grade 3, 2 patients), fatigue (grade 3, 4 patients), ascites (grade 3, 2 patients), and nausea/vomiting (grade 4, 2 patients). Five patients (45%) experienced stable disease with a median progression-free survival of 58 days (95% CI, 52-107 d). Conclusions: The maximum-tolerated dose is AEG35156 500 mg plus gemcitabine 1000 mg/m2 given on days 1, 8, and 15 every 28 days. AEG35156 plus gemcitabine failed to show significant clinical activity in advanced PDA.

XIAP

Pancreatic carcinoma

10.1097/coc.0b013e3182467a13

Cite

Citations (42)

Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies

American Journal of Clinical Oncology (2009)

Daruka Mahadevan Luke Dreisbach Timothy S. Kristedja Debbie Williams Yrma Obregon

Objectives: A Phase I study was initiated to investigate fixed dose rate gemcitabine (GEM) combined with epirubicin (EPI) given weekly or every other week, since, GEM given as a standard 30 minute infusion has modest activity. The study was designed based on the hypothesis that prolonged exposure (over 90 minutes) may improve response rates and combination with epirubicin (EPI) is synergistic. Methods: Eligible patients had measurable refractory solid malignancies with adequate bone marrow, renal, and liver functions. Patients received GEM 800, 1000, 1250 mg/m2 over 90 minutes followed by EPI 10 or 15 mg/m2 as a 30 minutes infusion on days 1, 8, and 15 or days 1 and 15 of a 28 day cycle. Results: Twenty-eight patients were enrolled and 24 are evaluable for overall toxicities and response rate. Toxicities include neutropenia (Gr 3 of Gr 4, 9 pts), thrombocytopenia (Gr 3 of Gr 4, 3 pts), fatigue (Gr 3 of Gr 4, 4 pts), and myalgia (Gr 3 of Gr 4, 1 pt). Dose limiting toxicity was grade 4 neutropenia. Seven patients experienced stable disease for >16 weeks and 3 patients with pancreatic cancer had partial responses. Conclusions: The maximum tolerated dose is GEM 800 mg/m2/EPI 10 mg/m2 days 1, 8, 15 or GEM 1000 mg/m2/EPI 15 mg/m2 days 1, 15 given every 4 weeks. Further studies are warranted with targeted therapies to define the efficacy of this doublet.

Epirubicin

myalgia

Leukopenia

10.1097/coc.0b013e31819cc9ed

Cite

Citations (2)

204 MDS PATIENT CHARACTERISTICS ASSOCIATED WITH USE OF DISEASE-MODIFYING THERAPY: RESULTS OF A PATIENT SURVEY

Leukemia Research (2015)

S. Kurtin E. Chang Tanya G. K. Bentley

Hypomethylating agent

10.1016/s0145-2126(15)30205-8

Cite